• Ensured compliance for the Patient Support Services (PSS) organization; worked closely with PSS leadership, Legal, Regulatory, Medical, Marketing Operations, Compliance & Quality Assurance and creative agencies • Managed the approval process for ≥200 pieces in Veeva PromoMats for multiple products; completed >400 Medical Legal & Regulatory (MLR) reviews in the first year including expiring documents varying from HCP and patient materials and vendor websites to HCP portal• Created, trained and implemented FDA Inspection Readiness process (onsite, remote and hybrid versions); facilitated mock inspection • Audit point of contact; assigned new hire and annual training for Standard Operating Procedures (SOP) to PSS employees, contractors and vendors; Maintained SOPs and submitted deviation reports as needed• Processed launch materials in MLR for LYBALVI (olanzapine and samidorphan) once-daily, oral atypical antipsychotic for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder• Chaired monthly Legal and PSS meeting; created and managed Legal SharePoint site, agenda and minutes and scheduled quarterly business reviews for vendor programs

• Supervised team of 6-8 Reimbursement Access Specialists (RAS) and Case Managers (CM) for VIVITROL® (Naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence and prevention of relapse to opioid dependence• Met department service level agreements (SLA) for CMs to triage patient scripts to specialty pharmacies within 24-48 hours upon receipt of patient enrollment form

• Launched ARISTADA® (aripiprazole lauroxil) long-acting injection for the treatment of schizophrenia in adults; provided reimbursement and access support to regional sales team • Resolved payer access issues and discussed trends with Managed Markets team• Subject Matter Expert (SME) for LASH Group AmerisourceBergen • Created HCP Attestation Form for patients without source of income for Patient Assistance Program (PAP) application• Developed and facilitated training workshops from Online Summary of Benefits for Medicare Part D and Advantage Plans, Low Income Subsidy (LIS) Overview, FAQs and Reimbursement Guide Exercises to Benefit Verification Report

• Launched VPRIV® the long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease• Coordinated patient services for the product Elaprase® indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)

• Launched OmniPod Insulin Management System®, the world’s first wireless diabetes pump • Key contributor to driving revenue to meet sales goals; top performer for converting patient referrals to patients on therapy • Exceeded quarterly goals, analyzed daily disposition reports and provided national tactical plan to team • Developed and managed the quality program to ensure medical policies were met prior to releasing product shipments resulting in increased paid claims; coached team on quality scores and submitted quarterly report to management • Negotiated letter of agreements (LOA) with non-contracted commercial plans • Decreased LOA approval timeframes by creating database with contact information of key decision makers in Utilization Review and Claims department enabling team to advocate through established channels; reported LOA trends by payer to Managed Markets to assist with contracting efforts• Liaison to service partner and distributor, conducted site visits and trained team to increase sales• Created insurance plan profiles that enabled team to efficiently navigate through payer specific challenges; included payer trends and medical policy highlights • Generated unforeseen revenue from converting closed cases to patients on therapy; initiative was key in meeting stretch goals • Implemented and designed new patient service model from “territory” to “stream” based using payer trends and contract status; decreased referral to on therapy processing times

• Launched TYSABRI® (natalizumab) infusible Multiple Sclerosis (MS) therapy • Located infusion sites, coordinated patient services and collaborated with sales field

• Administered financial assistance program, researched insurance benefits, and obtained prior authorizations for Avonex® (interferon beta-1a) injection for the treatment of relapsing forms of multiple sclerosis (MS)• Participated in the redevelopment of services to improve patient service model; reduced insurance verifications from 2 business days to 8 hours and extended enrollment period from 1 year to 2 years to maximize staffing resources• Prepared quarterly adverse event reports for internal audits by Drug Safety Medical Information and sited areas of improvement to patient services department • Liaison to service partner Accredo Health Group, Inc. (formerly Nova Factor), resolved case escalations and operational issues; conducted site visits and performed quality checks on electronic data transfer